Type 2 diabetes trials in Mexico

In Mexico 27 Also abroad 1200

27 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Where
Ciudad Madero, Col Saucito, Cuernavaca, Delegacion Cuauhtemoc, Guadalajara, México, San Pedro Garza García
Age
18 years and over
People
2,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00
Phase 3Taking people
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Where
Ciudad Madero, Col Saucito, Cuernavaca, Delegacion Cuauhtemoc, Guadalajara, México, San Pedro Garza García
Age
18 years and over
People
1,600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Where
Cuernavaca, Mexico City, Monterrey
Age
18 years and over
People
954 worldwide
Run by
Pfizer
See details and how to joinNCT07595549 · EU 2026-525318-75-00
Phase 3Taking people
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Where
Ciudad Madero, Guadalajara, Monterrey
Age
10 years to 17 years
People
170 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07668336 · EU 2025-524811-35-00
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Where
Guadalajara, Mérida, Monterrey
Age
18 years and over
People
1,035 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07282600 · EU 2025-523658-15-00
Phase 3Taking people
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Where
Chihuahua City, Guadalajara, Huixquilucan, Mexicali, Mexico City, Monterrey
Age
18 years and over
People
900 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07392190 · EU 2025-523659-73-00
Phase 3Not yet taking people in Mexico
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Where
Actopan, Cuernavaca, Culiacán, Durango, Guadalajara, León, México, Mexico City, Monterrey, Querétaro
Age
45 years to 64 years
People
3,000 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07900633 · EU 2026-525919-14-00
Phase 3Taking people
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Where
Cuernavaca, Guadalajara, Monterrey, San Luis Potosí City, Zapopan
Age
18 years and over
People
2,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662109 · EU 2025-523941-81-00
Phase 3Taking people
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Where
Chihuahua City, Cuernavaca, Culiacán, Guadalajara, Mérida, México, Mexico City, Monterrey, Torreón, Veracruz
Age
18 years and over
People
11,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07064473 · EU 2025-521188-11-00
No phaseTaking people
Continuous Glucose Monitoring in Patients With Diabetes on Peritoneal Dialysis
Where
Mexico City
Age
40 years to 70 years
People
110
Run by
Coordinación de Investigación en Salud, Mexico
See details and how to joinNCT06069518
No phaseNot yet taking people in Mexico
A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)
Where
Multiple Locations
Age
18 years and over
People
800
Run by
Bayer
See details and how to joinNCT07841015
Phase 3Taking people
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Where
Coyoacán, Cuauhtémoc, Monterrey, Puebla City, San Nicolás de los Garza
Age
10 years to 18 years
People
80 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07282613
No phaseTaking people
Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes
Where
Mexico City
Age
18 years and over
People
200
Run by
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
See details and how to joinNCT07835360
No phaseEnrolling by invitation
Glycemic Control and the Ask Me 3® Educational Program
Where
San Nicolás de los Garza
Age
18 years to 80 years
People
250
Run by
Maria Elena Romero Ibarguengoitia
See details and how to joinNCT07678671
No phaseTaking people
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
Where
Iztapalapa, León, México, Mexico City
Age
18 years and over
People
35,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT03549754
Phase 3Taking people
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
Where
Chihuahua City, Cuernavaca, Guadalajara, Mexico City, Monterrey, Zapopan
Age
18 years and over
People
900 worldwide
Run by
AstraZeneca
See details and how to joinNCT07662135 · EU 2025-523940-12-00
Phase 3Taking people
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
Where
Ciudad Madero, Guadalajara, Hermosillo, Mérida, Merida Centro, Monterrey, Tlalpan
Age
45 years and over
People
1,778 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT07797335
No phaseTaking people
Metformin Effects According to SLC16A11 Carrier Status
Where
Mexico City
Age
18 years to 65 years
People
154
Run by
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
See details and how to joinNCT07760883
Phase 3Taking people
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Where
Ciudad Madero, Puebla City, Tampico, Tlalpan, Veracruz
Age
10 years to 17 years
People
55 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06739122
Phase 3Not yet taking people in Mexico
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
Where
Guadalajara, Mexico City, Monterrey, Oaxaca City, Pachuca
Age
18 years and over
People
374
Run by
Carnot Laboratories
See details and how to joinNCT07628985
No phaseNot yet taking people in Mexico
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
Where
Mexico City
Age
18 years and over
People
30
Run by
JULIO GRANADOS MONTIEL
See details and how to joinNCT07567378
No phaseNot yet taking people in Mexico
Cohort Study of Metabolic Disease and Hypertension
Where
Mexico City
Age
18 years to 65 years
People
2,500
Run by
Coordinación de Investigación en Salud, Mexico
See details and how to joinNCT07577063
Phase 4Taking people
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
Where
Monterrey
Age
18 years and over
People
62
Run by
Hospital Universitario Dr. Jose E. Gonzalez
See details and how to joinNCT07401992
No phaseEnrolling by invitation
Type 2 Diabetes and Associated Factors in Mexico
Where
Mexico City
Age
18 years and over
People
1,000
Run by
Coordinación de Investigación en Salud, Mexico
See details and how to joinNCT07248891
No phaseEnrolling by invitation
Effect of Flaxseed as a Treatment for Adults With Type 2 Diabetes Mellitus in Mexico
Where
Oaxaca City
Age
30 years to 70 years
People
160
Run by
Universidad Autónoma Benito Juárez de Oaxaca
See details and how to joinNCT06683235